PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
PHO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. While PHO has a great health rating, there are worries on its profitability. While showing a medium growth rate, PHO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PHO had positive earnings in the past year.
PHO had a positive operating cash flow in the past year.
In the past 5 years PHO reported 4 times negative net income.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
PHO has a Return On Assets of 0.30%. This is in the lower half of the industry: PHO underperforms 64.00% of its industry peers.
PHO's Return On Equity of 0.45% is on the low side compared to the rest of the industry. PHO is outperformed by 64.00% of its industry peers.
PHO has a Return On Invested Capital of 1.79%. This is in the lower half of the industry: PHO underperforms 64.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROIC | 1.79% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHO has a Profit Margin of 0.40%. This is in the lower half of the industry: PHO underperforms 62.00% of its industry peers.
PHO has a Operating Margin of 2.64%. This is in the lower half of the industry: PHO underperforms 62.00% of its industry peers.
In the last couple of years the Operating Margin of PHO has declined.
With an excellent Gross Margin value of 93.97%, PHO belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
PHO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
PHO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHO has about the same amount of shares outstanding.
PHO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHO has been reduced compared to a year ago.
2.2 Solvency
PHO has an Altman-Z score of 5.00. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.00, PHO belongs to the best of the industry, outperforming 82.00% of the companies in the same industry.
PHO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5 |
ROIC/WACC0.21
WACC8.56%
2.3 Liquidity
PHO has a Current Ratio of 3.81. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.81, PHO belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
A Quick Ratio of 3.44 indicates that PHO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.44, PHO belongs to the top of the industry, outperforming 96.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The earnings per share for PHO have decreased strongly by -86.67% in the last year.
The Revenue has been growing slightly by 3.95% in the past year.
Measured over the past years, PHO shows a quite strong growth in Revenue. The Revenue has been growing by 13.29% on average per year.
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
3.2 Future
PHO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 190.44% yearly.
The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 2735.00, which means the current valuation is very expensive for PHO.
Compared to the rest of the industry, the Price/Earnings ratio of PHO indicates a slightly more expensive valuation: PHO is more expensive than 70.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PHO to the average of the S&P500 Index (27.21), we can say PHO is valued expensively.
With a Price/Forward Earnings ratio of 26.91, PHO can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 66.00% of the companies are valued more cheaply.
PHO's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.70.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2735 | ||
| Fwd PE | 26.91 |
4.2 Price Multiples
PHO's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHO is more expensive than 68.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHO is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.94 | ||
| EV/EBITDA | 28.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHO does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as PHO's earnings are expected to grow with 190.44% in the coming years.
PEG (NY)3.05
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
No dividends for PHO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (7/1/2025, 7:00:00 PM)
54.7
+0.6 (+1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners43.92%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap1.48B
Analysts82.5
Price Target79.05 (44.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.41%
Min EPS beat(2)-203.96%
Max EPS beat(2)15.13%
EPS beat(4)2
Avg EPS beat(4)-37.97%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)40.12%
EPS beat(12)6
Avg EPS beat(12)-9.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-5.24%
Max Revenue beat(2)-2.17%
Revenue beat(4)1
Avg Revenue beat(4)-3.95%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)3
Avg Revenue beat(8)-3.64%
Revenue beat(12)6
Avg Revenue beat(12)-2.7%
Revenue beat(16)7
Avg Revenue beat(16)-4.28%
PT rev (1m)-4.62%
PT rev (3m)-7.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)33.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2735 | ||
| Fwd PE | 26.91 | ||
| P/S | 2.78 | ||
| P/FCF | 22.94 | ||
| P/OCF | 19.59 | ||
| P/B | 3.14 | ||
| P/tB | 6.28 | ||
| EV/EBITDA | 28.11 |
EPS(TTM)0.02
EY0.04%
EPS(NY)2.03
Fwd EY3.72%
FCF(TTM)2.38
FCFY4.36%
OCF(TTM)2.79
OCFY5.11%
SpS19.64
BVpS17.4
TBVpS8.71
PEG (NY)3.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.3% | ||
| ROE | 0.45% | ||
| ROCE | 2.32% | ||
| ROIC | 1.79% | ||
| ROICexc | 3.13% | ||
| ROICexgc | 9.81% | ||
| OM | 2.64% | ||
| PM (TTM) | 0.4% | ||
| GM | 93.97% | ||
| FCFM | 12.14% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score5
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 38.09% | ||
| Cap/Sales | 2.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 175.53% | ||
| Profit Quality | 3024.79% | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 5 |
F-Score5
WACC8.56%
ROIC/WACC0.21
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-86.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.97%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)3.95%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%6.19%
Revenue Next Year11.38%
Revenue Next 2Y11.91%
Revenue Next 3Y11.59%
Revenue Next 5Y14.98%
EBIT growth 1Y-61.13%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year105.28%
EBIT Next 3Y59.66%
EBIT Next 5YN/A
FCF growth 1Y1030.99%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y590.65%
OCF growth 3Y47.56%
OCF growth 5Y30.02%